[Possible applications of rac-hopantenic acid in the treatment of anxiety and depressive disorders in patients with chronic cerebral ischemia]. / Vozmozhnosti primeneniya rats-gopantenovoi kisloty v kompleksnom lechenii trevozhno-depressivnykh rasstroistv u bol'nykh s khronicheskoi ishemiei golovnogo mozga.

AIM: To evaluate the efficacy and tolerability of rac-hopantenic acid (pantogam activ) in patients with mixed anxiety-depressive disorder and anxiety-depressive disorder with chronic cerebral ischemia. MATERIAL AND METHODS: A total of 50 patients were examined (30 patients in the main group, 20 patients in the control one). All patients received standard therapy with SSRI antidepressants. Rac-hopantenic acid at a daily dose of 1200 mg was included in the complex therapy of patients of the main group. Duration of the therapy with rac-hopantenic acid was 21 days. Psychopathological, psychometric and detailed somatic examinations were performed. RESULTS: In the main group, the combination of pantogam activ and antidepressants promoted distinct balanced nootropic, antidepressant and anxiolytic effects, as well as the improvement of health outcomes. The reduced total number of adverse events (less frequent drowsiness and headaches) was noted as well. CONCLUSION: The rapid and reliable reduction of anxiety, depression and cognitive impairment during concomitant therapy with antidepressants and pantogam activ was identified.

[The modern concept of remission in non-psychotic depressive disorders].

The modern concept of remission should take into account its multidimensional structure which includes the complex interaction between clinical (severity/nature of residual symptoms, types of clinical remission), subjective (social functioning and patient's assessment of their condition) and integrative (relapses) characteristics. Based on the study of 385 patients during pharmaco- and psychotherapy, it was shown that the leading role in this structure belongs to the clinical type of remission (full, mono-, poly-symptomatic remission and remission with the structure of minor depression) which, according to the dimensional approach, creates a continuum of states from the complete absence of any symptoms to subsyndromal depression. Subjective and integrative characteristics are determined by clinical types of remission.

[The formation of clinical and functional remission during the treatment of non-psychotic depression with escitalopram (lenuxin)].

The results of this study showed a high frequency of clinical remission (45.26%) during therapy of 98 patients with non-psychotic depression with escitalopram (lenuxin). However, the majority of patients (81.4%) had symptomatic remission presented with persistent isolated monosymptom of insomnia, anxiety, somatic-autonomic disorders or hypochondria spectrum. The complete recovery of social functioning (functional remission) in all areas (work, communication, family) was observed in 51.16% patients. The relationship between the severity of residual symptoms and functional remission justifies the need to include clinical and subjective indicators in a modern integrative concept of remission. The high efficacy of escitalopram (lenuxin) was combined with its favorable tolerability profile.